Novo Nordisk on November 11 announced steep price cut in its obesity drug Wegovy by up to 37 percent in India as it aims to expand access to chronic weight management therapy and take on rival weight loss drug Mounjaro.

The company announced that the starting dose of Wegovy (0.25 mg) will now cost Rs 2,712 per week, down from Rs 4,336—a move that significantly lowers the entry barrier for patients prescribed the once-weekly injectable.

Prices across all five dose strengths have been revised, with the highest dose (2.4 mg) now priced at Rs 4,100 per week.

Wegovy has already become slightly cheaper after GST rate was slashed from 12 percent to 5 percent in September 2025.

Novo Nordisk's price cut of Wegovy follows the company's partnership with Emcure Pharmaceuticals to commercialize Pov

See Full Page